Cefotaxime: Beta-Lactamase-Resistant Cephalosporin for Gram-Positive and Gram-Negative Bacteria

Executive Summary: Cefotaxime is a third-generation cephalosporin antibiotic stable against beta-lactamases, enabling robust inhibition of both Gram-positive and Gram-negative bacteria (APExBIO BA1012). Its molecular weight (455.47 Da) and formula (C16H17N5O7S2) support reliable dosing in research contexts (Cefotaxime: A Lactamase-Resistant Cephalosporin for Antimicrobial Resistance Research). Cefotaxime is a gold standard for benchmarking antimicrobial resistance and screening novel agents (Cefotaxime: A Benchmark Third-Generation Cephalosporin). Its effectiveness is maintained with proper storage at -20°C; solutions must be freshly prepared for experimental consistency (APExBIO). Cefotaxime enables detection of resistance mechanisms in multidrug-resistant Enterobacteriaceae, as shown in contemporary clinical surveillance (Chen et al., 2025).

Biological Rationale

Cefotaxime is a third-generation cephalosporin antibiotic designed to overcome the limitations of earlier beta-lactam antibiotics. Third-generation cephalosporins, such as Cefotaxime, are characterized by their enhanced activity against Gram-negative bacteria and increased resistance to hydrolysis by beta-lactamase enzymes produced by many clinical isolates (APExBIO). The prevalence of beta-lactamase-mediated resistance in hospital-acquired infections necessitates antibiotics with higher stability and spectrum. Cefotaxime’s broad-spectrum efficacy makes it a model compound in research focused on antimicrobial resistance and bacterial pathogenesis (see related article). This article expands upon previous summaries by integrating recent clinical surveillance data and molecular details.

Mechanism of Action of Cefotaxime

Cefotaxime exerts its antibacterial effect by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) within the bacterial cytoplasmic membrane, disrupting the transpeptidation step of peptidoglycan synthesis and leading to cell lysis (see Q&A on antibiotic mechanism). Its unique structure, with an oxyimino side chain, confers resistance to hydrolysis by most beta-lactamases, including extended-spectrum beta-lactamases (ESBLs). This mechanism is critical for efficacy against multidrug-resistant Gram-negative pathogens. However, carbapenemase-producing strains may still exhibit resistance, highlighting the importance of resistance gene surveillance (Chen et al., 2025).

Evidence & Benchmarks

• Cefotaxime demonstrates high in vitro efficacy against clinical isolates of Enterobacter cloacae, with resistance rates rising in carbapenemase-encoding gene (CEG)-positive strains (Chen et al., 2025).
• Broth microdilution assays confirm that CEG-positive Enterobacter cloacae have significantly higher resistance to cefepime, imipenem, and cefotaxime compared to CEG-negative strains, under standard laboratory conditions (35°C, Mueller-Hinton broth, 18–24 h) (Chen et al., 2025).
• Storage of Cefotaxime at -20°C preserves compound integrity for at least 12 months, but freshly prepared solutions are required for in vitro assays to avoid hydrolysis and loss of potency (APExBIO BA1012).
• Cefotaxime’s molecular weight is 455.47 Da and its formula is C16H17N5O7S2, allowing precise quantification for dose-response studies (Cefotaxime: A Lactamase-Resistant Cephalosporin).
• Cefotaxime is effective in both Gram-positive and Gram-negative bacterial infection models, validated across multiple research platforms (Cefotaxime: A Benchmark Third-Generation Cephalosporin).

Applications, Limits & Misconceptions

Cefotaxime is utilized in antimicrobial resistance research, bacterial pathogenesis studies, and for screening new antibiotic candidates. Its resistance to degradation by most beta-lactamases makes it a benchmark compound for evaluating ESBL and carbapenemase activity. However, its efficacy is diminished against bacteria producing certain carbapenemases (e.g., NDM-1) (Chen et al., 2025).

Common Pitfalls or Misconceptions

• Cefotaxime is not effective against all beta-lactamase-producing organisms; carbapenemase-positive strains may be resistant (Chen et al., 2025).
• Long-term storage of Cefotaxime in solution leads to degradation; only freshly prepared solutions should be used for assays (APExBIO).
• Cefotaxime is not intended for clinical or diagnostic use; it is for research purposes only (product page).
• Not all Gram-negative bacteria are equally susceptible; ESBL and carbapenemase gene carriage must be verified by molecular methods.

Workflow Integration & Parameters

Cefotaxime (SKU BA1012) from APExBIO is supplied as a solid, to be stored at -20°C. For solution preparation, dissolve in sterile water or appropriate buffer immediately before use; avoid freeze-thaw cycles. Shipping is performed with blue ice to maintain cold chain integrity (APExBIO BA1012). For in vitro susceptibility testing, standard protocols require 0.5–32 μg/mL concentration ranges, with incubation at 35°C for 18–24 hours in Mueller-Hinton broth. Quality control strains (e.g., E. coli ATCC 25922) are recommended for assay validation (related Q&A). This article augments previous workflow guidance by specifying storage and preparation parameters for maximum reproducibility.

Conclusion & Outlook

Cefotaxime remains a cornerstone in antimicrobial resistance research due to its stability against most beta-lactamases and broad-spectrum activity. However, resistance continues to evolve, particularly in carbapenemase-producing strains. Ongoing molecular surveillance and precise laboratory practices are essential for maintaining the reliability of Cefotaxime as a research standard. For detailed protocols and product parameters, refer to the Cefotaxime BA1012 product page from APExBIO.

This article extends the evidence base from previous internal reviews by integrating clinical surveillance data and emphasizing workflow-critical parameters. For further reading on mechanism and benchmark comparisons, see Cefotaxime: A Lactamase-Resistant Cephalosporin for Antimicrobial Resistance Research and Cefotaxime: A Benchmark Third-Generation Cephalosporin.